EAACI lança campanha global de conscientização sobre alergia a antibióticos no Congresso EAACI 2025 (EAACI Congress 2025)

ZURIQUE, Aug. 15, 2025 (GLOBE NEWSWIRE) — A EAACI lançou sua Campanha de Conscientização sobre Alergia a Antibióticos durante seu Congresso de 2025, realizado em Glasgow. A iniciativa dá início a um esforço global para abordar a rotulagem incorreta e sua ligação com a resistência antimicrobiana (RAM).

Uma chamada global à ação

A rotulagem incorreta de alergias a antibióticos afeta milhões de pessoas no mundo todo. Informações incorretas nos rótulos resultam na evitação de tratamentos de primeira linha e no uso excessivo de antibióticos de segunda linha, alimentando a RAM. A EAACI faz um apelo a todas as partes interessadas para que promovam o diagnóstico preciso e o uso responsável de antibióticos.

“Estamos lançando um movimento — não um momento”, declarou Maria Torres, presidente da EAACI. “Muitas vidas são impactadas pela não verificação das informações sobre alergias em rótulos, limitando as opções de tratamento e piorando os resultados em termos de saúde. Esta campanha cria uma dinâmica que favorece a correção de rótulos, uma melhora na segurança e a preservação dos antibióticos para as gerações futuras. Corrigir as informações dos rótulos significa salvar vidas — hoje e amanhã.”

Objetivos da campanha:

  • Ampliar a conscientização sobre os perigos da rotulagem incorreta de alergias a antibióticos
  • Capacitar os pacientes e profissionais de saúde com ferramentas e treinamento
  • Promover protocolos de avaliação de alergias amparados em evidências
  • Incentivar a prescrição racional dos antibióticos, a fim de proteger a eficácia em longo prazo

Superar os obstáculos

Muitos pacientes mantêm rótulos de alergia desatualizados, não verificados ou relatados pelos próprios pacientes, o que diminui as opções de tratamento e aumenta os riscos. A campanha aborda essas questões por meio de educação, treinamento e defesa dos direitos.

Recursos para impulsionar as mudanças

Um destaque central da campanha é um breve vídeo educativo que explica as alergias a antibióticos e por que as informações corretas em rótulos são importantes. O Kit Promocional 2025 oferece ferramentas para ampliar a campanha em todas as plataformas.

Junte–se ao movimento

Lançada sob o slogan “Correct Labels, Better Lives” (Rótulos corretos, vidas melhores), a campanha convida profissionais, educadores, instituições e indivíduos a se juntarem a este esforço global de conscientização. Juntos, podemos proteger a eficácia dos antibióticos.

Explore a campanha e baixe os recursos: https://eaaci.org/eaaci–antibiotic–allergy–awareness–campaign/

Sobre a EAACI

A Academia Europeia de Alergia e Imunologia Clínica (The European Academy of Allergy and Clinical Immunology, EAACI) é a maior associação profissional da Europa na área, comprometida em promover a pesquisa e o tratamento de pessoas afetadas por doenças alérgicas.

Saiba mais em https://eaaci.org

Contato: [email protected] | +41 44 205 55 33

Uma foto que acompanha este anúncio está disponível em http://www.globenewswire.com/NewsRoom/AttachmentNg/f2d7cd4b–652b–4207–9c07–315528446450


GLOBENEWSWIRE (Distribution ID 1001122910)

EAACI startet globale Aufklärungskampagne zu Antibiotikaallergien auf dem EAACI-Kongress 2025 (EAACI Congress 2025)

ZÜRICH, Aug. 15, 2025 (GLOBE NEWSWIRE) — Die EAACI hat im Rahmen ihres Kongresses 2025 in Glasgow ihre Aufklärungskampagne zum Thema Antibiotikaallergien gestartet. Die Initiative ist der Beginn einer weltweiten Kampagne gegen falsche Kennzeichnung und deren Zusammenhang mit Antibiotikaresistenzen (AMR).

Ein weltweiter Aufruf zum Handeln

Die falsche Kennzeichnung von Antibiotika–Allergien betrifft Millionen Menschen weltweit. Ungenaue Kennzeichnungen führen dazu, dass Erstlinienbehandlungen vermieden und Zweitlinienantibiotika übermäßig eingesetzt werden, was die AMR begünstigt. Die EAACI fordert alle Stakeholder auf, eine genaue Diagnose und einen verantwortungsvollen Einsatz von Antibiotika sicherzustellen.

„Wir starten eine Bewegung – nicht nur eine Momentaufnahme“, erklärte Maria Torres, Präsidentin der EAACI. „Zu viele Leben werden durch unbestätigte Allergiehinweise beeinträchtigt, die die Behandlungsmöglichkeiten einschränken und die Gesundheitsergebnisse verschlechtern. Diese Kampagne schafft Impulse, um Kennzeichnungen zu korrigieren, die Sicherheit zu verbessern und Antibiotika für künftige Generationen zu erhalten. Beschriftungen zu korrigieren bedeutet, Leben zu retten – jetzt und in Zukunft.“

Die Ziele der Kampagne:

  • Sensibilisierung für die Gefahren falscher Angaben zu Antibiotikaallergien
  • Stärken der Patienten und des medizinischen Fachpersonals mit Tools und Schulungen
  • Förderung evidenzbasierter Protokolle zur Allergieuntersuchung
  • Förderung einer rationalen Verschreibung von Antibiotika zum Schutz der langfristigen Wirksamkeit

Barrieren überwinden

Viele Patienten tragen veraltete, nicht verifizierte oder selbst erstellte Allergiehinweise bei sich, was die Behandlungsmöglichkeiten einschränkt und das Risiko erhöht. Die Kampagne befasst sich mit diesen Themen durch Aufklärung, Schulungen und Interessenvertretung.

Ressourcen für Veränderungen

Ein zentraler Bestandteil der Kampagne ist ein kurzes Informationsvideo, in dem Antibiotikaallergien erklärt werden und dargelegt wird, warum korrekte Kennzeichnungen wichtig sind. Das Werbekit 2025 enthält Instrumente, mit denen die Kampagne auf allen Plattformen verstärkt werden kann.

Werden Sie Teil der Bewegung

Die Kampagne wurde unter dem Motto „Correct Labels, Better Lives” (Korrekte Kennzeichnungen, besseres Leben) ins Leben gerufen und lädt Fachleute, Pädagogen, Institutionen und Einzelpersonen dazu ein, sich den weltweiten Bemühungen zur Sensibilisierung anzuschließen. Gemeinsam können wir die Wirksamkeit von Antibiotika schützen.

Entdecken Sie die Kampagne und laden Sie Ressourcen herunter: https://eaaci.org/eaaci–antibiotic–allergy–awareness–campaign/

Über die EAACI

Die Europäische Akademie für Allergien und klinische Immunologie (The European Academy of Allergy and Clinical Immunology, EAACI) ist Europas größter Berufsverband in diesem Bereich und engagiert sich für die Förderung der Forschung und Versorgung von Menschen, die von allergischen Erkrankungen betroffen sind.

Erfahren Sie mehr: https://eaaci.org

Kontakt: [email protected] | +41 44 205 55 33

Ein Foto zu dieser Mitteilung finden Sie unter http://www.globenewswire.com/NewsRoom/AttachmentNg/f2d7cd4b–652b–4207–9c07–315528446450


GLOBENEWSWIRE (Distribution ID 1001122910)

EAACI Launches Global Antibiotic Allergy Awareness Campaign at EAACI Congress 2025

ZURICH, Aug. 15, 2025 (GLOBE NEWSWIRE) — EAACI has launched its Antibiotic Allergy Awareness Campaign during its 2025 Congress in Glasgow. The initiative begins a global effort to address mislabelling and its link to antimicrobial resistance (AMR).

A Global Call to Action

Antibiotic allergy mislabelling affects millions worldwide. Inaccurate labels lead to avoidance of first–line treatments and overuse of second–line antibiotics, fuelling AMR. EAACI calls on all stakeholders to promote accurate diagnosis and responsible antibiotic use.

“We are launching a movement — not a moment,” said Maria Torres, EAACI President. “Too many lives are impacted by unverified allergy labels that limit treatment options and worsen health outcomes. This campaign builds momentum to correct labels, improve safety, and preserve antibiotics for future generations. Correcting labels means saving lives — now and in the future.”

The Campaign's Objectives:

  • Raise awareness about the dangers of incorrect antibiotic allergy labels
  • Empower patients and healthcare professionals with tools and training
  • Promote evidence–based allergy evaluation protocols
  • Encourage rational antibiotic prescribing to protect long–term efficacy

Breaking Down the Barriers

Many patients carry outdated, unverified, or self–reported allergy labels, reducing treatment options and increasing risk. The campaign tackles these issues through education, training, and advocacy.

Resources to Drive Change

A central feature of the campaign is a short educational video explaining antibiotic allergy and why correct labels matter. The Promotional Kit 2025 offers tools to amplify the campaign across all platforms.

Join the Movement

Launched under the slogan “Correct Labels, Better Lives,” the campaign invites professionals, educators, institutions, and individuals to join the global awareness effort. Together, we can protect the effectiveness of antibiotics.

Explore the campaign and download resources: https://eaaci.org/eaaci–antibiotic–allergy–awareness–campaign/

About EAACI

The European Academy of Allergy and Clinical Immunology (EAACI) is Europe’s largest professional association in the field, committed to advancing research and care for those affected by allergic diseases.

Learn more: https://eaaci.org

Contact: [email protected] | +41 44 205 55 33

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f2d7cd4b–652b–4207–9c07–315528446450


GLOBENEWSWIRE (Distribution ID 1001122912)

L’EAACI lance une campagne mondiale de sensibilisation aux allergies aux antibiotiques lors du EAACI Congress 2025

ZURICH, 15 août 2025 (GLOBE NEWSWIRE) — L’EAACI a lancé sa Antibiotic Allergy Awareness Campaign (Campagne de sensibilisation aux allergies aux antibiotiques) à l’occasion de son Congrès 2025 à Glasgow. Cette initiative marque le début d’un effort mondial visant à lutter contre les erreurs d’étiquetage et son lien avec la résistance aux antimicrobiens (RAM).

Un appel mondial à l’action

Les erreurs d’étiquetage relatives aux allergies aux antibiotiques touchent des millions de personnes dans le monde. Des mentions erronées conduisent à éviter les traitements de première intention et à surutiliser les antibiotiques de deuxième intention, favorisant ainsi la RAM. L’EAACI appelle l’ensemble des acteurs à promouvoir un diagnostic précis et un usage responsable des antibiotiques.

« Nous entamons une action à long terme, et non une initiative ponctuelle », a déclaré Maria Torres, présidente de l’EAACI. « Trop de vies sont affectées par des étiquettes d’allergie non vérifiées qui limitent les options de traitement et aggravent les résultats en matière de santé. Cette campagne vise à corriger ces étiquettes, améliorer la sécurité et préserver les antibiotiques pour les générations futures. Rectifier ces étiquettes, c’est sauver des vies, aujourd’hui et demain. »

Les objectifs de la campagne :

  • Sensibiliser aux dangers des mentions incorrectes d’allergie aux antibiotiques
  • Donner aux patients et aux professionnels de santé des outils et formations adaptés
  • Promouvoir des protocoles d’évaluation des allergies fondés sur des données probantes
  • Encourager une prescription raisonnée des antibiotiques afin d’en préserver l’efficacité à long terme

Faire tomber les barrières

De nombreux patients disposent d’étiquettes d’allergie obsolètes, non vérifiées ou auto–déclarées, qui limitent leurs options de traitement et augmentent les risques. La campagne cible ces problèmes par le biais de l’éducation, de la formation et de la sensibilisation.

Des ressources pour stimuler le changement

L’un des éléments clés de la campagne consiste en une courte vidéo éducative qui rappelle ce qu’est l’allergie aux antibiotiques et pourquoi il est crucial de disposer d’étiquettes adéquates. Le Promotional Kit 2025 met à disposition des outils pour promouvoir la campagne sur tous les canaux.

Rejoignez le mouvement

Lancées sous le slogan « Correct Labels, Better Lives » (Des étiquettes correctes, une vie meilleure), les actions de la campagne invitent professionnels, enseignants, institutions et particuliers à s’engager dans cette mobilisation mondiale. Ensemble, nous pouvons protéger l’efficacité des antibiotiques.

Découvrez la campagne et téléchargez les ressources : https://eaaci.org/eaaci–antibiotic–allergy–awareness–campaign/

À propos de l’EAACI

La Académie européenne d’allergologie et d’immunologie clinique (The European Academy of Allergy and Clinical Immunology, EAACI) est la plus grande association professionnelle européenne de ces domaines thérapeutiques. Elle s’engage à faire progresser la recherche et les soins pour les personnes atteintes de maladies allergiques.

Pour en savoir plus, rendez–vous sur https://eaaci.org

Cordonnées : [email protected] | +41 44 205 55 33

Une photo annexée au présent communiqué est disponible à l’adresse suivante : http://www.globenewswire.com/NewsRoom/AttachmentNg/f2d7cd4b–652b–4207–9c07–315528446450


GLOBENEWSWIRE (Distribution ID 1001122910)

Healthcare Innovation Summit Africa Returns to Johannesburg – Registration Now Open

JOHANNESBURG, South Africa, Aug. 14, 2025 (GLOBE NEWSWIRE) — The Healthcare Innovation Summit Africa (HISA) 2025, Africa’s leading platform for exploring the latest trends and technologies shaping the healthcare industry, will return to Johannesburg on 22 – 23 October 2025 for its 10th annual edition. Organised by IT News Africa, the event will gather senior healthcare professionals, government leaders, innovators, and technology providers from across Africa and beyond.

Themed “Connected Care, Smarter Systems: Building a Digitally Resilient African Health Ecosystem,” HISA 2025 will feature a robust agenda that covers critical areas such as artificial intelligence (AI), the Internet of Things (IoT), robotics, telemedicine, big data analytics, and digital transformation strategies for both public and private healthcare sectors.

Confirmed keynote and panel speakers include:

  • Dr Richard Friedland, Group CEO, Netcare
  • Dr. Boris Konrad, Neuroscientist, AI and Memory Expert, Radboudumc (Germany)
  • Andrew Raynes, CIO & SIRO, Royal Papworth Hospital (UK)
  • Nhlanhla Xaba, ICT Manager: Governance & Information Management, Mediclinic
  • Rajeev Eashwari, President, South African Health Informatics Association
  • Taryn Lotz, Head of IT, Aspen Pharmacare
  • Craig Killeen, CEO, Medinformer
  • Joost Pielage, CTO, Quro Medical
  • Quantin van Rensburg, CIO, Platinum Health Medical Scheme
  • Ish Hendricks, CEO, Netclinic

With Africa’s healthcare industry undergoing rapid transformation, HISA 2025 offers a unique opportunity for stakeholders to gain actionable insights and forge meaningful partnerships.

Delegates will benefit from:

  • Visionary keynote presentations from local and international thought leaders
  • Expert–led panel discussions tackling pressing healthcare challenges and opportunities
  • Exhibition showcases of innovative solutions, products, and services
  • Networking opportunities with policymakers, industry leaders, and innovators

Click here to register now

“HISA 2025 is not just a conference, it is where the future of African healthcare takes shape,” said the event organisers. “The event provides a powerful platform for collaboration, innovation, and the exchange of ideas that can positively impact healthcare systems across the continent.”

Event Details:
Date: 22 – 23 October 2025
Venue: Gallagher Convention Centre, Johannesburg, South Africa
Event Website: www.healthcareinnovationsummit.co.za

About HISA
The Healthcare Innovation Summit Africa is an annual gathering of healthcare professionals, innovators, and policymakers dedicated to exploring and implementing technology–driven solutions that improve healthcare delivery across Africa.


GLOBENEWSWIRE (Distribution ID 1001122873)

Healthcare Innovation Summit Africa Returns to Johannesburg – Registration Now Open

JOHANNESBURG, South Africa, Aug. 14, 2025 (GLOBE NEWSWIRE) — The Healthcare Innovation Summit Africa (HISA) 2025, Africa’s leading platform for exploring the latest trends and technologies shaping the healthcare industry, will return to Johannesburg on 22 – 23 October 2025 for its 10th annual edition. Organised by IT News Africa, the event will gather senior healthcare professionals, government leaders, innovators, and technology providers from across Africa and beyond.

Themed “Connected Care, Smarter Systems: Building a Digitally Resilient African Health Ecosystem,” HISA 2025 will feature a robust agenda that covers critical areas such as artificial intelligence (AI), the Internet of Things (IoT), robotics, telemedicine, big data analytics, and digital transformation strategies for both public and private healthcare sectors.

Confirmed keynote and panel speakers include:

  • Dr Richard Friedland, Group CEO, Netcare
  • Dr. Boris Konrad, Neuroscientist, AI and Memory Expert, Radboudumc (Germany)
  • Andrew Raynes, CIO & SIRO, Royal Papworth Hospital (UK)
  • Nhlanhla Xaba, ICT Manager: Governance & Information Management, Mediclinic
  • Rajeev Eashwari, President, South African Health Informatics Association
  • Taryn Lotz, Head of IT, Aspen Pharmacare
  • Craig Killeen, CEO, Medinformer
  • Joost Pielage, CTO, Quro Medical
  • Quantin van Rensburg, CIO, Platinum Health Medical Scheme
  • Ish Hendricks, CEO, Netclinic

With Africa’s healthcare industry undergoing rapid transformation, HISA 2025 offers a unique opportunity for stakeholders to gain actionable insights and forge meaningful partnerships.

Delegates will benefit from:

  • Visionary keynote presentations from local and international thought leaders
  • Expert–led panel discussions tackling pressing healthcare challenges and opportunities
  • Exhibition showcases of innovative solutions, products, and services
  • Networking opportunities with policymakers, industry leaders, and innovators

Click here to register now

“HISA 2025 is not just a conference, it is where the future of African healthcare takes shape,” said the event organisers. “The event provides a powerful platform for collaboration, innovation, and the exchange of ideas that can positively impact healthcare systems across the continent.”

Event Details:
Date: 22 – 23 October 2025
Venue: Gallagher Convention Centre, Johannesburg, South Africa
Event Website: www.healthcareinnovationsummit.co.za

About HISA
The Healthcare Innovation Summit Africa is an annual gathering of healthcare professionals, innovators, and policymakers dedicated to exploring and implementing technology–driven solutions that improve healthcare delivery across Africa.


GLOBENEWSWIRE (Distribution ID 1001122873)

Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis

JERUSALEM, July 28, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and protein replacement therapies, announced today that in a written response to a Type A meeting request, the U.S. Food and Drug Administration (FDA) agreed with the Company’s proposal that the NDA marketing application filing for EB613 would be supported by a single multinational, randomized, double–blind, placebo–controlled, 24 month phase 3 study in women with postmenopausal osteoporosis, where change in total hip BMD is evaluated as the primary endpoint, and incidence of new or worsening vertebral fractures is evaluated as the key secondary endpoint. This marks a shift from precedent placebo–controlled phase 3 studies of new osteoporosis drugs which required incidence of fracture as the primary endpoint.

“This regulatory update is a major milestone for Entera and the entire osteoporosis community,” said Miranda Toledano, CEO of Entera. “Our alignment with the FDA reflects the strength of our data and collaborative discussions. Importantly, it allows us to advance our clinical development program without having to wait for FDA’s qualification of the Study to Advance Bone Mineral Density as a Regulatory Endpoint (SABRE), which is still expected this year. We thank the FDA and the Review Team at the Division of Endocrinology for their constructive approach. We also thank the SABRE team for paving the path to innovation for osteoporosis treatment,” said Toledano.

“Osteoporosis afflicts more women than heart attack, stroke and breast cancer combined. Over 200 million women globally are estimated to have osteoporosis and remain vastly undertreated, despite efficacious injectable anabolic (bone forming) treatments. One in two women over the age of 50 will suffer a fracture due to osteoporosis. No new drug for osteoporosis has been approved by FDA since 2019; and innovation has stalled for close to a decade due to the size, duration, cost and ethical constraints associated with fracture endpoint studies. In a silent disease, patient and clinician access to novel and alternative forms of validated mechanisms of action is important. We are developing EB613 as the first oral, once–daily anabolic tablet treatment to potentially serve this unmet medical need. EB613 is intended to increase skeletal mass, improve bone microarchitecture and reduce the risk of fracture,” said Miranda Toledano, CEO of Entera.

About EB613

Substantial evidence supports the efficacy of anabolic therapies over bisphosphonates for lowering fracture risk in osteoporosis patients at high risk. However, all available anabolic therapies are administered by subcutaneous (SC) injection and used in a minority of eligible patients. EB613 (oral PTH (1–34), teriparatide), is being developed as the first oral, once–daily anabolic tablet treatment for osteoporosis. EB613 completed a phase 2, 6–month, 161–patient, placebo–controlled study that met all biomarker and BMD endpoints without significant safety concerns in women with postmenopausal osteoporosis or low BMD (JBMR 2024). EB613 produced rapid dose–proportional increases in biochemical markers of bone formation, reductions in markers of bone resorption, and increased lumbar spine, total hip, and femoral neck BMD. The effects of EB613 on trabecular and cortical bone using 3D–DXA showed increases with EB613 compared with placebo in a variety of indices, including integral volumetric BMD and trabecular volumetric BMD, cortical thickness, and cortical surface BMD. Mechanistically, the findings suggest that bone strengthening, and fracture resistance may occur rapidly with EB613. Furthermore, the data are consistent with those of published subcutaneous teriparatide at the 6–month time point. Further abstracts have been submitted to ASBMR and NAMS 2025 conferences.

About Entera Bio

Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform (N–Tab™) and its pipeline of first–in–class oral peptide programs targeting PTH(1–34), GLP–1 and GLP–2. The Company’s most advanced product candidate, EB613 (oral PTH(1–34), teriparatide), is being developed as the first oral, osteoanabolic (bone building) once–daily tablet treatment for post–menopausal women with low BMD and high–risk osteoporosis. A placebo–controlled, dose–ranging Phase 2 study of EB613 tablets (n= 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). The EB612 program is being developed as the first oral PTH(1–34) tablet peptide replacement therapy for hypoparathyroidism. Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic syndromes; and first oral GLP–2 peptide as an injection–free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health. For more information on Entera Bio, visit www.enterabio.com or follow us on LinkedIn, Twitter, Facebook, Instagram.

About SABRE

The Study to Advance BMD as a Regulatory Endpoint (SABRE) initiative, which started as a public private partnership sponsored by the FNIH in 2013, has amassed the strongest evidence to date that treatment–related gains in Bone Mineral Density (BMD) reliably and quantitatively predict fracture–risk reduction. In November 2023, the SABRE team submitted a full qualification package to FDA’s Biomarker Division as part of the Drug Development Tool Biomarker Qualification Pathway to potentially qualify BMD as a surrogate endpoint to fracture; in March 2024, the FDA Biomarker Division indicated to the SABRE project team that a decision would be issued within 10 months. The single most important predictor of osteoporotic fractures in postmenopausal women without a previous fracture is BMD. Treatment guidelines in the U.S. strongly recommend pharmacologic therapy for patients with a BMD T–score of –2.5 or lower in the spine, femoral neck, total hip. SABRE final FQP meta–analysis included data from 22 randomized, placebo–controlled trials (63,000 participants across seven drug classes) and showed that treatment–related gains in total–hip BMD explain 72% of the observed fracture–risk reduction. The R2 for this correlation was 0.73—double the correlation between blood pressure and stroke (R² = 0.37), which is the well accepted basis for the value of antihypertensive therapy.

Cautionary Statement Regarding Forward Looking Statements

Various statements in this presentation are “forward–looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this presentation regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward–looking statements. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward–looking statements. Forward–looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward–looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved.

Important factors that could cause actual results to differ materially from those reflected in Entera’s forward–looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA’s interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources, either by Entera or its collaboration and laboratory partners; impacts to research and development or clinical activities that Entera may be contractually obligated to provide; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing Entera’s product candidates; Entera’s reliance on third parties to conduct its clinical trials; Entera’s ability to establish and maintain development and commercialization collaborations; Entera’s operation as a development stage company with limited operating history; Entera’s competitive position with respect to other products on the market or in development for the treatment of osteoporosis, hypoparathyroidism, short bowel syndrome, obesity, metabolic conditions and other disease categories it pursues; Entera’s ability to continue as a going concern absent access to sources of liquidity; Entera’s ability to obtain and maintain regulatory approval for any of its product candidates; Entera’s ability to comply with Nasdaq’s minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera’s intellectual property position and its ability to protect its intellectual property; and other factors that are described in the “Cautionary Statement Regarding Forward–Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of Entera’s most recent Annual Report on Form 10–K filed with the SEC, as well as Entera’s subsequently filed Quarterly Reports on Form 10–Q and Current Reports on Form 8–K. There can be no assurance that the actual results or developments anticipated by Entera will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera. Therefore, no assurance can be given that the outcomes stated or implied in such forward–looking statements and estimates will be achieved. Entera cautions investors not to rely on the forward–looking statements Entera makes in this presentation. The information in this presentation is provided only as of the date of this presentation, and Entera undertakes no obligation to update or revise publicly any forward–looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.


GLOBENEWSWIRE (Distribution ID 9501141)

EAACI-Führung blickt auf rekordverdächtigen Kongress 2025 zurück: Ein entscheidender Moment für Allergologie und Immunologie

ZÜRICH, July 17, 2025 (GLOBE NEWSWIRE) — Mit über 7.600 Teilnehmern hat der EAACI–Kongress 2025 nicht nur aufgrund seiner Größe Schlagzeilen gemacht, sondern auch aufgrund der eindringlichen Botschaft seiner Führungskräfte. Nun, einen Monat nach Abschluss des Kongresses in Glasgow, teilen die führenden Vertreter der EAACI ihre Überlegungen zu diesem, wie sie es bezeichnen, Wendepunkt für den Bereich mit. Die Veranstaltung fand vom 13. bis 16. Juni im Scottish Event Campus statt und stand unter dem Motto: „Grenzen überwinden in Allergie, Asthma und klinischer Immunologie: Integration der globalen Gesundheit für eine nachhaltige Zukunft“.

„Der diesjährige Kongress war ein Wendepunkt“, so Prof. Maria Torres, Präsidentin der EAACI. „Wir treten in eine Ära ein, in der wissenschaftliche Innovation, Gleichberechtigung in der Gesundheitsversorgung und Umweltgesundheit gemeinsam vorangetrieben werden müssen.“

Das Programm umfasste über 250 Stunden Vorträge, Workshops und Symposien zu bahnbrechenden Fortschritten in den Bereichen Arzneimittelallergien, T2–Entzündungen, Asthma bei Kindern und hereditäres Angioödem. Das Präsidialsymposium befasste sich mit Antibiotikaresistenzen aus der Perspektive von „One Health“, während eine aktuelle Sitzung zu Klimawandel und Insektenallergien die weltweite Aufmerksamkeit auf die ökologischen Auswirkungen auf die Patientenversorgung lenkte.

Weit über die Mauern des SEC hinaus hat der EAACI–Kongress 2025 die gesamte Stadt mit Initiativen belebt, die die Wissenschaft auf die Straße gebracht haben. Das Clinical Village im Glasgow Science Centre empfing die Öffentlichkeit zu einer interaktiven Allergieaufklärung, während der Beat Allergy Walk & Run Spenden für die Glasgow Children’s Hospital Charity sammelte und damit die Verpflichtung der EAACI für soziale Verantwortung und gesellschaftliches Engagement bekräftigte.

„Der Geist der Zusammenarbeit, den wir in Glasgow erlebt haben, war außergewöhnlich“, so Prof. André Moreira, EAACI Vice President Congresses. „Diese Energie wird nun in konkrete Initiativen und globale Partnerschaften umgesetzt.“

Der Kongress hob auch das Engagement der EAACI für Mentoring, digitale Gesundheitsinnovationen und die Stärkung der Patientenrechte hervor.

Der Countdown für den EAACI–Kongress 2026 in Istanbul hat offiziell begonnen, aber Sie müssen nicht bis dahin warten, um wieder in die Welt der Spitzenforschung einzutauchen. Von gezielten Meetings bis hin zu praxisorientierten Kursen – die EAACI bietet Ihnen ein umfangreiches Programm, das Sie das ganze Jahr über inspirieren wird. Informieren Sie sich über die nächsten Termine unter https://eaaci.org.

Über die EAACI
Die European Academy of Allergy and Clinical Immunology (EAACI) ist Europas größter Fachverband in diesem Bereich und hat sich der Förderung der Forschung und Versorgung von Menschen mit allergischen Erkrankungen verschrieben.

Erfahren Sie mehr: https://eaaci.org

Kontakt: [email protected] | +41 44 205 55 33

Ein Foto zu dieser Mitteilung ist verfügbar unter http://www.globenewswire.com/NewsRoom/AttachmentNg/60c21700–f7c9–486c–a72f–f699174a926a


GLOBENEWSWIRE (Distribution ID 1001118256)

Liderança da EAACI reflete sobre o Congresso Recorde de 2025: um momento crucial para as áreas de Alergia e Imunologia

ZURIQUE, July 17, 2025 (GLOBE NEWSWIRE) — Com mais de 7.600 delegados presentes, o Congresso da EAACI 2025 foi manchete não apenas por sua magnitude, mas pela mensagem poderosa transmitida por sua liderança. Agora, um mês após a conclusão do Congresso em Glasgow, as principais figuras da EAACI estão compartilhando suas reflexões sobre o que eles chamam de um divisor de águas para o campo. Realizado de 13 a 16 de junho no Scottish Event Campus, o evento defendeu o tema: “Rompendo fronteiras nas áreas de alergia, asma e imunologia clínica: integração da saúde planetária para um futuro sustentável”.

“O Congresso deste ano foi um divisor de águas”, declarou a Profa. Maria Torres, Presidente da EAACI. “Estamos entrando em uma era na qual a inovação científica, a equidade no atendimento e a saúde ambiental devem avançar de maneira conjunta.”

O programa contou com mais de 250 horas de palestras, workshops e simpósios, abordando avanços inovadores em alergia a medicamentos, inflamação tipo 2 (T2), asma pediátrica e angioedema hereditário. O Simpósio Presidencial abordou a resistência antimicrobiana pela perspectiva da Saúde Única, enquanto uma sessão oportuna sobre as mudanças climáticas e a alergia a insetos chamou a atenção global para os impactos ecológicos no atendimento aos pacientes.

Muito além dos muros da SEC, o Congresso da EAACI 2025 movimentou toda a cidade com iniciativas que levaram a ciência às ruas. A Vila Clínica, localizada no Centro de Ciências de Glasgow, recebeu o público para uma atividade educacional prática sobre alergias, enquanto a caminhada e corrida Beat Allergy Walk & Run arrecadou fundos para a Organização Beneficente do Hospital Infantil de Glasgow, reforçando o compromisso da EAACI com o impacto social e o engajamento comunitário.

“O espírito de colaboração que testemunhamos em Glasgow foi extraordinário”, declarou o Prof. André Moreira, Vice–Presidente de Congressos da EAACI. “Essa energia agora se traduz em iniciativas reais e parcerias globais.”

O Congresso também destacou a dedicação da EAACI à mentoria, à inovação em saúde digital e à amplificação das vozes dos pacientes.

A contagem regressiva para o Congresso da EAACI 2026 em Istambul começou oficialmente, mas você não precisará esperar até lá para mergulhar outra vez na ciência de ponta. De reuniões para tratar temas específicos a cursos práticos, a EAACI tem uma agenda repleta de opções para mantê–lo inspirado o ano todo. Confira o que vem por aí em https://eaaci.org.

Sobre a EAACI
A Academia Europeia de Alergia e Imunologia Clínica (EAACI) é a maior associação profissional da Europa na área, comprometida em promover a pesquisa e o tratamento de pessoas afetadas por doenças alérgicas.

Saiba mais em https://eaaci.org

Contato: [email protected] | +41 44 205 55 33

Uma foto que acompanha este anúncio está disponível em http://www.globenewswire.com/NewsRoom/AttachmentNg/60c21700–f7c9–486c–a72f–f699174a926a


GLOBENEWSWIRE (Distribution ID 1001118256)

La direction de l’EAACI fait le point sur son remarquable congrès 2025 représentant un tournant décisif pour l’allergologie et l’immunologie

ZURICH, 17 juill. 2025 (GLOBE NEWSWIRE) — Le congrès 2025 de l’EAACI a fait couler beaucoup d’encre à l’appui de ses 7 600 participants et plus, de son envergure et du message fort porté par son comité directeur. Un mois après la clôture de l’événement qui s’est tenu à Glasgow, les figures de proue de l’EAACI reviennent collectivement sur ce qu’ils qualifient de tournant décisif. Organisé du 13 au 16 juin au Scottish Event Campus, le congrès était placé sous le thème suivant : « Repousser les limites dans les domaines de l’allergie, de l’asthme et de l’immunologie clinique et intégrer la santé planétaire pour un avenir durable ».

Pour la professeure Maria Torres, présidente de l’EAACI, « Le congrès de cette année marque un véritable tournant. Nous entrons dans une phase où l’innovation scientifique, l’équité de traitement et la santé environnementale doivent avancer ensemble ».

Le programme s’est décliné en plus de 250 heures de conférences, d’ateliers et de symposiums et a permis de présenter des avancées majeures dans des domaines thérapeutiques comme l’allergie médicamenteuse, l’inflammation de type 2, l’asthme pédiatrique ou encore l’angioœdème héréditaire. Le symposium présidentiel a exposé la résistance aux antimicrobiens sous l’angle de l’approche « One Health » (une santé commune à tous) tandis qu’une session très attendue portant sur le changement climatique et les allergies aux insectes a attiré l’attention du monde entier sur les impacts écologiques des soins aux patients.

Bien au–delà des murs du Scottish Event Campus, le congrès EAACI 2025 a fait vivre tout Glasgow au rythme de projets entendant rapprocher la science du grand public. Installé au musée scientifique de la ville, le « Clinical Village » (village clinique) a proposé un enseignement pratique ciblé sur les allergies aux visiteurs, tandis que la course « Beat Allergy Walk & Run » visait à collecter des fonds destinés à l’association caritative Glasgow Children’s Hospital Charity. Ces deux événements viennent renforcer l’engagement de l’EAACI en faveur de l’impact social et de l’engagement collectif.

« Nous avons pu observer un formidable esprit de collaboration à Glasgow » indique le professeur André Moreira, vice–président du Congrès de l’EAACI. « Toute cette belle énergie se traduit désormais par des initiatives concrètes et des partenariats conclus à l’échelle mondiale ».

Le congrès a également permis de souligner l’engagement de l’EAACI en faveur du mentorat, de l’innovation en santé numérique, et de l’écho donné à la voix des patients.

Le compte à rebours du congrès EAACI 2026 organisé à Istanbul est désormais lancé, mais vous n’avez nul besoin d’attendre cet événement pour vous replonger dans la science de pointe. En effet, l’EAACI propose un calendrier nourri de réunions ciblées et de formations pratiques pour abreuver vos connaissances tout au long de l’année. Nous vous invitions à prendre connaissance des prochains événements depuis la page : https://eaaci.org.

À propos de l’EAACI
L’Académie européenne d’allergologie et d’immunologie clinique (EAACI) est la plus grande association professionnelle européenne de ces domaines thérapeutiques. Elle s’engage à faire progresser la recherche et les soins pour les personnes atteintes de maladies allergiques.

Pour en savoir plus, rendez–vous sur https://eaaci.org

Cordonnées : [email protected] | +41 44 205 55 33

Une photo annexée au présent communiqué est disponible à l’adresse suivante : http://www.globenewswire.com/NewsRoom/AttachmentNg/60c21700–f7c9–486c–a72f–f699174a926a


GLOBENEWSWIRE (Distribution ID 1001118256)